Analysts Set Artivion, Inc. (NYSE:AORT) Price Target at $49.11

Artivion, Inc. (NYSE:AORT) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $49.1143.

A number of brokerages have recently issued reports on AORT. Oppenheimer reiterated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Needham & Company LLC boosted their target price on shares of Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, November 7th. JMP Securities increased their price target on shares of Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Artivion from a “buy” rating to a “strong-buy” rating in a research note on Sunday.

Artivion Stock Performance

Artivion stock opened at $46.79 on Thursday. Artivion has a fifty-two week low of $21.97 and a fifty-two week high of $48.25. The company has a market capitalization of $2.22 billion, a PE ratio of -194.97 and a beta of 1.60. The company has a 50 day moving average price of $45.06 and a 200-day moving average price of $39.52. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.14 by $0.02. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. The business had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. The company’s quarterly revenue was up 18.9% on a year-over-year basis. As a group, equities analysts forecast that Artivion will post 0.37 earnings per share for the current year.

Insider Activity

In related news, CEO James P. Mackin sold 30,921 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $45.56, for a total value of $1,408,760.76. Following the completion of the transaction, the chief executive officer directly owned 800,993 shares of the company’s stock, valued at $36,493,241.08. This trade represents a 3.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Amy Horton sold 4,572 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $44.42, for a total value of $203,088.24. Following the completion of the transaction, the chief accounting officer directly owned 130,058 shares in the company, valued at approximately $5,777,176.36. The trade was a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 234,511 shares of company stock worth $10,612,452. Company insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On Artivion

Large investors have recently bought and sold shares of the company. Oppenheimer Asset Management Inc. bought a new position in shares of Artivion in the 2nd quarter worth about $669,000. Kennedy Capital Management LLC raised its stake in Artivion by 20.8% during the second quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock worth $11,437,000 after acquiring an additional 63,205 shares during the period. Invesco Ltd. lifted its holdings in Artivion by 27.9% in the first quarter. Invesco Ltd. now owns 341,656 shares of the company’s stock worth $8,398,000 after acquiring an additional 74,589 shares during the last quarter. Fred Alger Management LLC acquired a new position in Artivion in the first quarter valued at approximately $2,969,000. Finally, Atria Investments Inc bought a new position in shares of Artivion during the second quarter valued at approximately $244,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.